Search

Your search keyword '"ALINGS, MARCO"' showing total 555 results
Start Over Author "ALINGS, MARCO"
555 results on '"ALINGS, MARCO"'

151. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Author

Pol, Tymon, primary, Held, Claes, additional, Westerbergh, Johan, additional, Lindbäck, Johan, additional, Alexander, John H., additional, Alings, Marco, additional, Erol, Cetin, additional, Goto, Shinya, additional, Halvorsen, Sigrun, additional, Huber, Kurt, additional, Hanna, Michael, additional, Lopes, Renato D., additional, Ruzyllo, Witold, additional, Granger, Christopher B., additional, and Hijazi, Ziad, additional

Published
2018
Full Text
View/download PDF

152. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Author

Connolly, Stuart J, primary, Eikelboom, John W, additional, Bosch, Jackie, additional, Dagenais, Gilles, additional, Dyal, Leanne, additional, Lanas, Fernando, additional, Metsarinne, Kaj, additional, O'Donnell, Martin, additional, Dans, Anthony L, additional, Ha, Jong-Won, additional, Parkhomenko, Alexandr N, additional, Avezum, Alvaro A, additional, Lonn, Eva, additional, Lisheng, Liu, additional, Torp-Pedersen, Christian, additional, Widimsky, Petr, additional, Maggioni, Aldo P, additional, Felix, Camilo, additional, Keltai, Katalin, additional, Hori, Masatsugu, additional, Yusoff, Khalid, additional, Guzik, Tomasz J, additional, Bhatt, Deepak L, additional, Branch, Kelley R H, additional, Cook Bruns, Nancy, additional, Berkowitz, Scott D, additional, Anand, Sonia S, additional, Varigos, John D, additional, Fox, Keith A A, additional, Yusuf, Salim, additional, SALA, JORGELINA, additional, CARTASEGNA, LUIS, additional, VICO, MARISA, additional, HOMINAL, MIGUEL ANGEL, additional, HASBANI, EDUARDO, additional, CACCAVO, ALBERTO, additional, ZAIDMAN, CESAR, additional, VOGEL, DANIEL, additional, HRABAR, ADRIAN, additional, SCHYGIEL, PABLO OMAR, additional, CUNEO, CARLOS, additional, LUQUEZ, HUGO, additional, MACKINNON, IGNACIO J., additional, AHUAD GUERRERO, RODOLFO ANDRES, additional, COSTABEL, JUAN PABLO, additional, BARTOLACCI, INES PALMIRA, additional, MONTANA, OSCAR, additional, BARBIERI, MARIA, additional, GOMEZ VILAMAJO, OSCAR, additional, GARCIA DURAN, RUBEN OMAR, additional, SCHIAVI, LILIA BEATRIZ, additional, GARRIDO, MARCELO, additional, INGARAMO, ADRIAN, additional, BORDONAVA, ANSELMO PAULINO, additional, PELAGAGGE, MARIA JOSE, additional, NOVARETTO, LEONARDO, additional, ALBISU DI GENNERO, JUAN PABLO, additional, IBANEZ SAGGIA, LUZ MARIA, additional, ALVAREZ, MOIRA, additional, VITA, NESTOR ALEJANDRO, additional, MACIN, STELLA MARIS, additional, DRAN, RICARDO DARIO, additional, CARDONA, MARCELO, additional, GUZMAN, LUIS, additional, SARJANOVICH, RODOLFO JUAN, additional, CUADRADO, JESUS, additional, NANI, SEBASTIAN, additional, LITVAK BRUNO, MARCOS RAUL, additional, CHACON, CAROLINA, additional, MAFFEI, LAURA ELENA, additional, GRINFELD, DIEGO, additional, VENSENTINI, NATALIA, additional, MAJUL, CLAUDIO RODOLFO, additional, LUCIARDI, HECTOR LUCAS, additional, GONZALEZ COLASO, PATRICIA DEL CARMEN, additional, FERRE PACORA, FREDY ANTONI, additional, VAN DEN HEUVEL, PAUL, additional, VERHAMME, PETER, additional, ECTOR, BAVO, additional, DEBONNAIRE, PHILIPPE, additional, VAN DE BORNE, PHILIPPE, additional, LEROY, JEAN, additional, SCHROE, HERMAN, additional, VRANCKX, PASCAL, additional, ELEGEERT, IVAN, additional, HOFFER, ETIENNE, additional, DUJARDIN, KARL, additional, INDIO DO BRASIL, CLARISSE, additional, PRECOMA, DALTON, additional, ABRANTES, JOSE ANTONIO, additional, MANENTI, EULER, additional, REIS, GILMAR, additional, SARAIVA, JOSE, additional, MAIA, LILIA, additional, HERNANDES, MAURO, additional, ROSSI, PAULO, additional, ROSSI DOS SANTOS, FABIO, additional, ZIMMERMANN, SERGIO LUIZ, additional, RECH, RAFAEL, additional, ABIB JR, EDUARDO, additional, LEAES, PAULO, additional, BOTELHO, ROBERTO, additional, DUTRA, OSCAR, additional, SOUZA, WEIMAR, additional, BRAILE, MARIA, additional, IZUKAWA, NILO, additional, NICOLAU, JOSE CARLOS, additional, TANAJURA, LUIZ FERNANDO, additional, SERRANO JUNIOR, CARLOS VICENTE, additional, MINELLI, CESAR, additional, NASI, LUIZ ANTONIO, additional, OLIVEIRA, LIVIA, additional, DE CARVALHO CANTARELLI, MARCELO JOSE, additional, TYTUS, RICHARD, additional, PANDEY, SHEKHAR, additional, LONN, EVA, additional, CHA, JAMES, additional, VIZEL, SAUL, additional, BABAPULLE, MOHAN, additional, LAMY, ANDRE, additional, SAUNDERS, KEVIN, additional, BERLINGIERI, JOSEPH, additional, KIAII, BOB, additional, BHARGAVA, RAKESH, additional, MEHTA, PRAVINSAGAR, additional, HILL, LAURIE, additional, FELL, DAVID, additional, LAM, ANDY, additional, AL-QOOFI, FAISAL, additional, BROWN, CRAIG, additional, PETRELLA, ROBERT, additional, RICCI, JOSEPH A, additional, GLANZ, ANTHONY, additional, NOISEUX, NICOLAS, additional, BAINEY, KEVIN, additional, MERALI, FATIMA, additional, HEFFERNAN, MICHAEL, additional, DELLA SIEGA, ANTHONY, additional, DAGENAIS, GILLES R, additional, DAGENAIS, FRANCOIS, additional, BRULOTTE, STEEVE, additional, NGUYEN, MICHEL, additional, HARTLEIB, MICHAEL, additional, GUZMAN, RANDOLPH, additional, BOURGEOIS, RONALD, additional, RUPKA, DENNIS, additional, KHAYKIN, YAARIV, additional, GOSSELIN, GILBERT, additional, HUYNH, THAO, additional, PILON, CLAUDE, additional, CAMPEAU, JEAN, additional, PICHETTE, FRANCIS, additional, DIAZ, ARIEL, additional, JOHNSTON, JAMES, additional, SHUKLE, PRAVIN, additional, HIRSCH, GREGORY, additional, RHEAULT, PAUL, additional, CZARNECKI, WLODZIMIERZ, additional, ROY, ANNIE, additional, NAWAZ, SHAH, additional, FREMES, STEPHEN, additional, SHUKLA, DINKAR, additional, JANO, GABRIEL, additional, COBOS, JORGE LEONARDO, additional, CORBALAN, RAMON, additional, MEDINA, MARCELO, additional, NAHUELPAN, LEONARDO, additional, RAFFO, CARLOS, additional, PEREZ, LUIS, additional, POTTHOFF, SERGIO, additional, STOCKINS, BENJAMIN, additional, SEPULVEDA, PABLO, additional, PINCETTI, CHRISTIAN, additional, VEJAR, MARGARITA, additional, TIAN, HONGYAN, additional, WU, XUESI, additional, KE, YUANNAN, additional, JIA, KAIYING, additional, YIN, PENGFEI, additional, WANG, ZHAOHUI, additional, YU, LITIAN, additional, WU, SHULIN, additional, WU, ZONGQUI, additional, LIU, SHAO WEN, additional, BAI, XIAO JUAN, additional, ZHENG, YANG, additional, YANG, PING, additional, YANG, YUN MEI, additional, ZHANG, JIWEI, additional, GE, JUNBO, additional, CHEN, XIAO PING, additional, LI, JUNXIA, additional, HU, TAO HONG, additional, ZHANG, RUIYAN, additional, ZHENG, ZHE, additional, CHEN, XIN, additional, TAO, LIANG, additional, LI, JIANPING, additional, HUANG, WEIJIAN, additional, FU, GUOSHENG, additional, LI, CHUNJIAN, additional, DONG, YUGANG, additional, WANG, CHUNSHENG, additional, ZHOU, XINMIN, additional, KONG, YE, additional, SOTOMAYOR, ARISTIDES, additional, ACCINI MENDOZA, JOSE LUIS, additional, CASTILLO, HENRY, additional, URINA, MIGUEL, additional, AROCA, GUSTAVO, additional, PEREZ, MARITZA, additional, MOLINA DE SALAZAR, DORA INES, additional, SANCHEZ VALLEJO, GREGORIO, additional, FERNANDO, MANZUR J, additional, GARCIA, HENRY, additional, GARCIA, LUIS HERNANDO, additional, ARCOS, EDGAR, additional, GOMEZ, JUAN, additional, CUERVO MILLAN, FRANCISCO, additional, TRUJILLO DADA, FREDY ALBERTO, additional, VESGA, BORIS, additional, MORENO SILGADO, GUSTAVO ADOLFO, additional, ZIDKOVA, EVA, additional, LUBANDA, JEAN-CLAUDE, additional, KALETOVA, MARKETA, additional, KRYZA, RADIM, additional, MARCINEK, GABRIEL, additional, RICHTER, MAREK, additional, SPINAR, JINDRICH, additional, MATUSKA, JIRI, additional, TESAK, MARTIN, additional, MOTOVSKA, ZUZANA, additional, BRANNY, MARIAN, additional, MALY, JIRI, additional, MALY, MARTIN, additional, WIENDL, MARTIN, additional, FOLTYNOVA CAISOVA, LENKA, additional, SLABY, JOSEF, additional, VOJTISEK, PETR, additional, PIRK, JAN, additional, SPINAROVA, LENKA, additional, BENESOVA, MIROSLAVA, additional, CANADYOVA, JULIA, additional, HOMZA, MIROSLAV, additional, FLORIAN, JINDRICH, additional, POLASEK, ROSTISLAV, additional, COUFAL, ZDENEK, additional, SKALNIKOVA, VLADIMIRA, additional, BRAT, RADIM, additional, BRTKO, MIROSLAV, additional, JANSKY, PETR, additional, LINDNER, JAROSLAV, additional, MARCIAN, PAVEL, additional, STRAKA, ZBYNEK, additional, TRETINA, MARTIN, additional, DUARTE, YAN CARLOS, additional, POW CHON LONG, FREDDY, additional, SANCHEZ, MAYRA, additional, LOPEZ, JOSE, additional, PERUGACHI, CARMITA, additional, MARMOL, RICARDO, additional, TRUJILLO, FREDDY, additional, TERAN, PABLO, additional, TUOMILEHTO, JAAKKO, additional, TUOMILEHTO, HENRI, additional, TUOMINEN, MARJA-LEENA, additional, KANTOLA, ILKKA, additional, STEG, GABRIEL, additional, ABOYANS, VICTOR, additional, LECLERCQ, FLORENCE, additional, FERRARI, EMILE, additional, BOCCARA, FRANCK, additional, MESSAS, EMMANUEL, additional, MISMETTI, PATRICK, additional, SEVESTRE, MARIE ANTOINETTE, additional, CAYLA, GUILLAUME, additional, MOTREFF, PASCAL, additional, STOERK, STEFAN, additional, DUENGEN, HANS-DIRK, additional, STELLBRINK, CHRISTOPH, additional, GUEROCAK, OSMAN, additional, KADEL, CHRISTOPH, additional, BRAUN-DULLAEUS, RUEDIGER, additional, JESERICH, MICHAEL, additional, OPITZ, CHRISTIAN, additional, VOEHRINGER, HANS-FRIEDRICH, additional, APPEL, KARL-FRIEDRICH, additional, WINKELMANN, BERNHARD, additional, DORSEL, THOMAS, additional, NIKOL, SIGRID, additional, DARIUS, HARALD, additional, RANFT, JURGEN, additional, SCHELLONG, SEBASTIAN, additional, JUNGMAIR, WOLFGANG, additional, DAVIERWALA, PIROZE, additional, VORPAHL, MARC, additional, BAJNOK, LASZLO, additional, LASZLO, ZOLTAN, additional, NOORI, EBRAHIM, additional, VERESS, GABOR, additional, VERTES, ANDRAS, additional, ZSARY, ANDRAS, additional, KIS, ERNO, additional, KORANYI, LASZLO, additional, BAKAI, JUDIT, additional, BODA, ZOLTAN, additional, POOR, FERENC, additional, JARAI, ZOLTAN, additional, KEMENY, VENDEL, additional, BARTON, JOHN, additional, MCADAM, BRENDAN, additional, MURPHY, ANDREW, additional, CREAN, PETER, additional, MAHON, NIALL, additional, CURTIN, RONAN, additional, MACNEILL, BRIAIN, additional, DINNEEN, SEAN, additional, HALABI, MAJDI, additional, ZIMLICHMAN, REUVEN, additional, ZELTSER, DAVID, additional, TURGEMAN, YOAV, additional, KLAINMAN, ELIEZER, additional, LEWIS, BASIL, additional, KATZ, AMOS, additional, ATAR, SHAUL, additional, NIKOLSKY, EUGENIA, additional, BOSI, STEFANO, additional, NALDI, MONICA, additional, FAGGIANO, POMPILIO, additional, ROBBA, DEBORA, additional, MOS, LUCIO, additional, SINAGRA, GIANFRANCO, additional, COSMI, FRANCO, additional, OLTRONA VISCONTI, LUIGI, additional, CARMINE, DE MATTEIS, additional, DI PASQUALE, GIUSEPPE, additional, DI BIASE, MATTEO, additional, MANDORLA, SARA, additional, BERNARDINANGELI, MARINO, additional, PICCINNI, GIOVANNI CARLO, additional, GULIZIA, MICHELE MASSIMO, additional, GALVANI, MARCELLO, additional, VENTURI, FLAVIO, additional, MOROCUTTI, GIORGIO, additional, BALDIN, MARIA GRAZIA, additional, OLIVIERI, CARLO, additional, PERNA, GIAN PIERO, additional, CIRRINCIONE, VINCENZO, additional, KANNO, TAKAYASU, additional, DAIDA, HIROYUKI, additional, OZAKI, YUKIO, additional, MIYAMOTO, NAOMASA, additional, HIGASHIUE, SHINICHI, additional, DOMAE, HIROSHI, additional, HOSOKAWA, SHINOBU, additional, KOBAYASHI, HIROO, additional, KURAMOCHI, TAKEHIKO, additional, FUJII, KENSHI, additional, MIZUTOMI, KAZUAKI, additional, SAKU, KEIJIRO, additional, KIMURA, KAZUO, additional, HIGUCHI, YOSHIHARU, additional, ABE, MITSUNORI, additional, OKUDA, HARUHITO, additional, NODA, TOSHIYUKI, additional, MITA, TERUAKI, additional, HIRAYAMA, ATSUSHI, additional, ONAKA, HARUHIKO, additional, INOKO, MORIAKI, additional, HIROKAMI, MITSUGU, additional, OKUBO, MUNENORI, additional, AKATSUKA, YUTAKA, additional, IMAMAKI, MIZUHO, additional, KAMIYA, HARUO, additional, MANITA, MAMORU, additional, HIMI, TOSHIHARU, additional, UENO, HIDEKI, additional, HISAMATSU, YUJI, additional, AKO, JUNYA, additional, NISHINO, YASUHIRO, additional, KAWAKAMI, HIDEO, additional, YAMADA, YUTAKA, additional, KORETSUNE, YUKIHIRO, additional, YAMADA, TAKAHISA, additional, YOSHIDA, TETSURO, additional, SHIMOMURA, HIDEKI, additional, KINOSHITA, NORIYUKI, additional, TAKAHASHI, AKIHIKO, additional, YUSOFF, KHALID, additional, WAN AHMAD, WAN AZMAN, additional, ABU HASSAN, MUHAMMAD RADZI, additional, KASIM, SAZZLI, additional, ABDUL RAHIM, AIZAI AZAN, additional, MOHD ZAMRIN, DIMON, additional, MACHIDA, MASAHARU, additional, HIGASHINO, YORIHIKO, additional, UTSU, NORIAKI, additional, NAKANO, AKIHIKO, additional, NAKAMURA, SHIGERU, additional, HASHIMOTO, TETSUO, additional, ANDO, KENJI, additional, SAKAMOTO, TOMOHIRO, additional, PRINS, F.J., additional, LOK, DIRK, additional, MILHOUS, JOHANNES GERT-JAN, additional, VIERGEVER, ERIC, additional, WILLEMS, FRANK, additional, SWART, HENK, additional, ALINGS, MARCO, additional, BREEDVELD, ROB, additional, DE VRIES, KEES-JAN, additional, VAN DER BORGH, ROGER, additional, OEI, FANNY, additional, ZOET-NUGTEREN, STIENEKE, additional, KRAGTEN, HANS, additional, HERRMAN, JEAN PAUL, additional, VAN BERGEN, PAUL, additional, GOSSELINK, MARCEL, additional, HOEKSTRA, EDUARD, additional, ZEGERS, ERWIN, additional, RONNER, EELKO, additional, DEN HARTOG, FRANK, additional, BARTELS, GERARD, additional, NIEROP, PETER, additional, VAN DER ZWAAN, COEN, additional, VAN ECK, JACOB, additional, VAN GORSELEN, EDWIN, additional, GROENEMEIJER, BJORN, additional, HOOGSLAG, PIETER, additional, DE GROOT, MARC ROBERT, additional, LOYOLA, ALDRIN, additional, SULIT, DENNIS JOSE, additional, REY, NANNETTE, additional, ABOLA, MARIA TERESA, additional, MORALES, DANTE, additional, PALOMARES, ELLEN, additional, ABAT, MARC EVANS, additional, ROGELIO, GREGORIO, additional, CHUA, PHILIP, additional, DEL PILAR, JOSE CARLO, additional, ALCARAZ, JOHN DENNIS, additional, EBO, GERALDINE, additional, TIRADOR, LOUIE, additional, CRUZ, JOSEFINA, additional, ANONUEVO, JOHN, additional, PITARGUE, ARTHUR, additional, JANION, MARIANNA, additional, GUZIK, TOMASZ, additional, GAJOS, GRZEGORZ, additional, ZABOWKA, MACIEJ, additional, RYNKIEWICZ, ANDRZEJ, additional, BRONCEL, MARLENA, additional, SZUBA, ANDRZEJ, additional, CZARNECKA, DANUTA, additional, MAGA, PAWEL, additional, STRAZHESKO, IRINA, additional, VASYUK, YURY, additional, SIZOVA, ZHANNA, additional, POZDNYAKOV, YURY, additional, BARBARASH, OLGA, additional, VOEVODA, MIKHAIL, additional, POPONINA, TATIANA, additional, REPIN, ALEXEY, additional, OSIPOVA, IRINA, additional, EFREMUSHKINA, ANNA, additional, NOVIKOVA, NINA, additional, AVERKOV, OLEG, additional, ZATEYSHCHIKOV, DMITRY, additional, VERTKIN, ARKADIY, additional, AUSHEVA, AZA, additional, COMMERFORD, PATRICK, additional, SEEDAT, SAADIYA, additional, VAN ZYL, LOUIS, additional, ENGELBRECHT, JAN, additional, MAKOTOKO, ELLEN MAKONLI, additional, PRETORIUS, CATHARINA ELIZABETH, additional, MOHAMED, ZAID, additional, HORAK, ADRIAN, additional, MABIN, THOMAS, additional, KLUG, ERIC, additional, BAE, JANG-HO, additional, KIM, CHEOLHO, additional, KIM, CHONG-JIN, additional, KIM, DONG-SOO, additional, KIM, YONG JIN, additional, JOO, SEUNGJAE, additional, HA, JONG-WON, additional, PARK, CHUL SOO, additional, KIM, JANG YOUNG, additional, KIM, YOUNG-KWON, additional, JARNERT, CHRISTINA, additional, MOOE, THOMAS, additional, DELLBORG, MIKAEL, additional, TORSTENSSON, INGEMAR, additional, ALBERTSSON, PER, additional, JOHANSSON, LARS, additional, AL-KHALILI, FARIS, additional, ALMROTH, HENRIK, additional, ANDERSSON, TOMMY, additional, PANTEV, EMIL, additional, TENGMARK, BENGT-OLOV, additional, LIU, BO, additional, RASMANIS, GUNDARS, additional, WAHLGREN, CARL-MAGNUS, additional, MOCCETTI, TIZIANO, additional, PARKHOMENKO, ALEXANDER, additional, TSELUYKO, VIRA, additional, VOLKOV, VOLODYMYR, additional, KOVAL, OLENA, additional, KONONENKO, LYUDMYLA, additional, PROKHOROV, OLEKSANDR, additional, VDOVYCHENKO, VALERIY, additional, BAZYLEVYCH, ANDRIY, additional, RUDENKO, LEONID, additional, VIZIR, VADYM, additional, KARPENKO, OLEKSANDR, additional, MALYNOVSKY, YAROSLAV, additional, KOVAL, VALENTYNA, additional, STOROZHUK, BORYS, additional, COTTON, JAMES, additional, VENKATARAMAN, ASOK, additional, MORIARTY, ANDREW, additional, CONNOLLY, DEREK, additional, DAVEY, PATRICK, additional, SENIOR, ROXY, additional, BIRDI, INDERPAUL, additional, CALVERT, JOHN, additional, DONNELLY, PATRICK, additional, TREVELYAN, JASPER, additional, CARTER, JUSTIN, additional, PEACE, AARON, additional, AUSTIN, DAVID, additional, KUKREJA, NEVILLE, additional, HILTON, THOMAS, additional, SRIVASTAVA, SUNNY, additional, WALSH, RONALD, additional, FIELDS, RONALD, additional, HAKAS, JOSEPH, additional, PORTNAY, EDWARD, additional, GOGIA, HARINDER, additional, SALACATA, ABRAHAM, additional, HUNTER, JOHN J., additional, BACHARACH, J MICHAEL, additional, SHAMMAS, NICOLAS, additional, SURESH, DAMODHAR, additional, SCHNEIDER, RICKY, additional, GURBEL, PAUL, additional, BANERJEE, SUBHASH, additional, GRENA, PAUL, additional, BEDWELL, NOEL, additional, SLOAN, STEPHEN, additional, LUPOVITCH, STEVEN, additional, SONI, ANAND, additional, GIBSON, KATHLEEN, additional, SANGRIGOLI, RENEE, additional, MEHTA, RAJENDRA, additional, I-HSUAN TSAI, PETER, additional, GILLESPIE, EVE, additional, DEMPSEY, STEPHEN, additional, HAMROFF, GLENN, additional, BLACK, ROBERT, additional, LADER, ELLIS, additional, KOSTIS, JOHN B., additional, BITTNER, VERA, additional, MCGUINN, WILLIAM, additional, BRANCH, KELLEY, additional, MALHOTRA, VINAY, additional, MICHAELSON, STEPHEN, additional, VACANTE, MICHAEL, additional, MCCORMICK, MATTHEW, additional, ARIMIE, RALUCA, additional, CAMP, ALAN, additional, DAGHER, GEORGE, additional, KOSHY, N. MATHEW, additional, THEW, STEPHEN, additional, COSTELLO, FREDERICK, additional, HEIMAN, MARK, additional, CHILTON, ROBERT, additional, MORAN, MICHAEL, additional, ADLER, FREDRIC, additional, COMEROTA, ANTHONY, additional, SEIWERT, ANDREW, additional, FRENCH, WILLIAM, additional, SEROTA, HARVEY, additional, HARRISON, ROBERT, additional, BAKAEEN, FAISAL, additional, OMER, SHUAB, additional, CHANDRA, LOKESH, additional, WHELAN, ALAN, additional, BOYLE, ANDREW, additional, ROBERTS-THOMSON, PHILIP, additional, ROGERS, JAMES, additional, CARROLL, PATRICK, additional, COLQUHOUN, DAVID, additional, SHAW, JAMES, additional, BLOMBERY, PETER, additional, AMERENA, JOHN, additional, HII, CHRIS, additional, ROYSE, ALISTAIR, additional, SINGH, BHUWAN, additional, SELVANAYAGAM, JOSEPH, additional, JANSEN, SHIRLEY, additional, LO, WINGCHI, additional, HAMMETT, CHRISTOPHER, additional, POULTER, ROHAN, additional, NARASIMHAN, SESHASAYEE, additional, WIGGERS, HENRIK, additional, NIELSEN, HENRIK, additional, GISLASON, GUNNAR, additional, KOBER, LARS, additional, HOULIND, KIM, additional, BOENELYKKE SOERENSEN, VIBEKE, additional, DIXEN, ULRIK, additional, REFSGAARD, JENS, additional, ZEUTHEN, ELISABETH, additional, SOEGAARD, PETER, additional, HRANAI, MARIAN, additional, GASPAR, LUDOVIT, additional, PELLA, DANIEL, additional, HATALOVA, KATARINA, additional, DROZDAKOVA, ERIKA, additional, COMAN, IOAN, additional, DIMULESCU, DOINA, additional, VINEREANU, DRAGOS, additional, CINTEZA, MIRCEA, additional, SINESCU, CRINA, additional, ARSENESCU, CATALINA, additional, BENEDEK, IMRE, additional, BOBESCU, ELENA, additional, DOBREANU, DAN, additional, GAITA, DAN, additional, IANCU, ADRIAN, additional, ILIESIU, ADRIANA, additional, LIGHEZAN, DANIEL, additional, PETRESCU, LUCIAN, additional, PIRVU, OCTAVIAN, additional, TEODORESCU, IULIA, additional, TESLOIANU, DAN, additional, VINTILA, MARIUS MARCIAN, additional, and CHIONCEL, OVIDIU, additional

Published
2018
Full Text
View/download PDF

153. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation : Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Author

Westenbrink, B. Daan, Alings, Marco, Granger, Christopher B., Alexander, John H., Lopes, Renato D., Hylek, Elaine M., Thomas, Laine, Wojdyla, Daniel M., Hanna, Michael, Keltai, Matyas, Steg, P. Gabriel, De Caterina, Raffaele, Wallentin, Lars, van Gilst, Wick H., Westenbrink, B. Daan, Alings, Marco, Granger, Christopher B., Alexander, John H., Lopes, Renato D., Hylek, Elaine M., Thomas, Laine, Wojdyla, Daniel M., Hanna, Michael, Keltai, Matyas, Steg, P. Gabriel, De Caterina, Raffaele, Wallentin, Lars, and van Gilst, Wick H.

Abstract

Background Patients with atrial fibrillation (AF) are prone to cardiovascular events and anticoagulation-related bleeding complications. We hypothesized that patients with anemia are at increased risk for these outcomes. Methods We performed a post hoc analysis of the ARISTOTLE trial, which included >18,000 patients with AF randomized to warfarin (target international normalized ratio, 2.0-3.0) or apixaban 5 mg twice daily. Multivariable Cox regression analysis was used to determine if anemia (defined as hemoglobin <13.0 in men and <12.0 g/dL in women) was associated with future stroke, major bleeding, or mortality. Results Anemia was present at baseline in 12.6% of the ARISTOTLE population. Patients with anemia were older, had higher mean CHADS2 and HAS-BLED scores, and were more likely to have experienced previous bleeding events. Anemia was associated with major bleeding (adjusted hazard ratio [HR], 1.92; 95% CI, 1.62-2.28; P < .0001) and all-cause mortality (adjusted HR, 1.68; 95% CI, 1.46-1.93; P <. 0001) but not stroke or systemic embolism (adjusted HR, 0.92; 95% CI, 0.70-1.21). The benefits of apixaban compared with warfarin on the rates of stroke, mortality, and bleeding events were consistent in patients with and without anemia. Conclusions Chronic anemia is associated with a higher incidence of bleeding complications and mortality, but not of stroke, in anticoagulated patients with AF. Apixaban is an attractive anticoagulant for stroke prevention in patients with AF with or without anemia.

Published
2017
Full Text
View/download PDF

155. Nationwide Longitudinal Follow-Up of Riata Leads Under Advisory at 3 Annual Screenings: Report From the Netherlands Heart Rhythm Association Device Advisory Committee

Author

Cardiologie, Circulatory Health, Team Medisch, Theuns, Dominic A M J, van Erven, Lieselot, Kimman, Geert P., de Cock, Carel C., Elvan, Arif, Alings, Marco A., van Opstal, Jurren, Meine, Mathias, Cardiologie, Circulatory Health, Team Medisch, Theuns, Dominic A M J, van Erven, Lieselot, Kimman, Geert P., de Cock, Carel C., Elvan, Arif, Alings, Marco A., van Opstal, Jurren, and Meine, Mathias

Published
2017

156. Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial

Author

Bosch, Jackie, primary, Eikelboom, John W., additional, Connolly, Stuart J., additional, Bruns, Nancy Cook, additional, Lanius, Vivian, additional, Yuan, Fei, additional, Misselwitz, Frank, additional, Chen, Edmond, additional, Diaz, Rafael, additional, Alings, Marco, additional, Lonn, Eva M., additional, Widimsky, Petr, additional, Hori, Masatsugu, additional, Avezum, Alvaro, additional, Piegas, Leopoldo S., additional, Bhatt, Deepak L., additional, Branch, Kelley R.H., additional, Probstfield, Jeffrey L., additional, Liang, Yan, additional, Liu, Lisheng, additional, Zhu, Jun, additional, Maggioni, Aldo P., additional, Lopez-Jaramillo, Patricio, additional, O'Donnell, Martin, additional, Fox, Keith A.A., additional, Kakkar, Ajay, additional, Parkhomenko, Alexander N., additional, Ertl, Georg, additional, Störk, Stefan, additional, Keltai, Katalin, additional, Keltai, Matyas, additional, Ryden, Lars, additional, Dagenais, Gilles R., additional, Pogosova, Nana, additional, Dans, Antonio L., additional, Lanas, Fernando, additional, Commerford, Patrick J., additional, Torp-Pedersen, Christian, additional, Guzik, Tomasz J., additional, Verhamme, Peter B., additional, Vinereanu, Dragos, additional, Kim, Jae-Hyung, additional, Ha, Jong-Won, additional, Tonkin, Andrew M., additional, Varigos, John D., additional, Lewis, Basil S., additional, Felix, Camilo, additional, Yusoff, Khalid, additional, Steg, Philippe Gabriel, additional, Aboyans, Victor, additional, Metsarinne, Kaj P., additional, Anand, Sonia S., additional, Hart, Robert G., additional, Lamy, Andre, additional, Moayyedi, Paul, additional, Leong, Darryl P., additional, Sharma, Mukul, additional, and Yusuf, Salim, additional

Published
2017
Full Text
View/download PDF

157. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial

Author

Lopes, Renato D., primary, Alings, Marco, additional, Connolly, Stuart J., additional, Beresh, Heather, additional, Granger, Christopher B., additional, Mazuecos, Juan Benezet, additional, Boriani, Giuseppe, additional, Nielsen, Jens C., additional, Conen, David, additional, Hohnloser, Stefan H., additional, Mairesse, Georges H., additional, Mabo, Philippe, additional, Camm, A. John, additional, and Healey, Jeffrey S., additional

Published
2017
Full Text
View/download PDF

159. Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.

Author

With, Ruben R De, Rienstra, Michiel, Smit, Marcelle D, Weijs, Bob, Zwartkruis, Victor W, Hobbelt, Anne H, Alings, Marco, Tijssen, Jan G P, Brügemann, Johan, Geelhoed, Bastiaan, Hillege, Hans L, Tukkie, Raymond, Hemels, Martin E, Tieleman, Robert G, Ranchor, Adelita V, Veldhuisen, Dirk J Van, Crijns, Harry J G M, Gelder, Isabelle C Van, De With, Ruben R, and Van Veldhuisen, Dirk J

Abstract

Aims: Atrial fibrillation (AF) reduces quality of life (QoL). We aim to evaluate effects of targeted therapy of underlying conditions on QoL in patients with AF and heart failure (HF).Methods and Results: The Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) study randomized patients with early persistent AF and HF to targeted or conventional therapy. Both groups received guideline-driven treatment. The targeted group received four additional therapies: mineralocorticoid receptor antagonists; statins; angiotensin converting enzyme inhibitors and/or receptor blockers; and cardiac rehabilitation including physical activity, dietary restrictions, and counselling. Quality of life was analysed in 230 patients at baseline and 1 year with available Medical Outcomes Study Short-Form Health Survey (SF-36), University of Toronto AF Severity Scale (AFSS) questionnaires, and European Heart Rhythm Association (EHRA) class. Improvements in SF-36 subscales were larger in the targeted group for physical functioning (Δ12 ± 19 vs. Δ6 ± 22, P = 0.007), physical role limitations (Δ32 ± 41 vs. Δ17 ± 45, P = 0.018), and general health (Δ8 ± 16 vs. Δ0 ± 17, P < 0.001). Dyspnoea at rest improved more (Δ-0.8 ± 1.3 vs. Δ-0.4 ± 1.2, P = 0.018) and EHRA class was lower at 1-year follow-up in the targeted group. Patients with AF at 1 year, improvement in physical functioning (Δ9 ± 9 vs. Δ-3 ± 16, P = 0.001), general health (Δ7 ± 16 vs. Δ-7 ± 19, P = 0.004), and social functioning (Δ6 ± 23 vs. Δ-4 ± 16, P = 0.041) were larger in the targeted group.Conclusion: A strategy aiming to treat underlying conditions improved QoL more compared with conventional therapy in patients with early persistent AF and HF. Its benefit was even observed in patients in AF at 1 year.Trial Registration Number: Clinicaltrials.gov NCT00877643. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

160. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

Author

Heidbuchel, Hein, primary, Verhamme, Peter, additional, Alings, Marco, additional, Antz, Matthias, additional, Diener, Hans-Christoph, additional, Hacke, Werner, additional, Oldgren, Jonas, additional, Sinnaeve, Peter, additional, Camm, A. John, additional, and Kirchhof, Paulus, additional

Published
2016
Full Text
View/download PDF

164. The complexity after simplicity: how to proceed with renal denervation in hypertension?

Author

MS Nefrologie, Circulatory Health, Cardiovasculaire Epi Team 10, Cardiologie, Cardiovasculaire Epi Team 9, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Blankestijn, Peter J., Alings, Marco, Voskuil, Michiel, Grobbee, DE, MS Nefrologie, Circulatory Health, Cardiovasculaire Epi Team 10, Cardiologie, Cardiovasculaire Epi Team 9, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Blankestijn, Peter J., Alings, Marco, Voskuil, Michiel, and Grobbee, DE

Published
2015

165. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.

Author

Rienstra, Michiel, Hobbelt, Anne H, Alings, Marco, Tijssen, Jan G P, Smit, Marcelle D, Brügemann, Johan, Geelhoed, Bastiaan, Tieleman, Robert G, Hillege, Hans L, and Tukkie, Raymond

Abstract

Aims Atrial fibrillation (AF) is a progressive disease. Targeted therapy of underlying conditions refers to interventions aiming to modify risk factors in order to prevent AF. We hypothesised that targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent AF. Methods and results We randomized patients with early persistent AF and mild-to-moderate heart failure (HF) to targeted therapy of underlying conditions or conventional therapy. Both groups received causal treatment of AF and HF, and rhythm control therapy. In the intervention group, on top of that, four therapies were started: (i) mineralocorticoid receptor antagonists (MRAs), (ii) statins, (iii) angiotensin converting enzyme inhibitors and/or receptor blockers, and (iv) cardiac rehabilitation including physical activity, dietary restrictions, and counselling. The primary endpoint was sinus rhythm at 1 year during 7 days of Holter monitoring. Of 245 patients, 119 were randomized to targeted and 126 to conventional therapy. The intervention led to a contrast in MRA (101 [85%] vs. 5 [4%] patients, P  < 0.001) and statin use (111 [93%] vs. 61 [48%], P  < 0.001). Angiotensin converting enzyme inhibitors/angiotensin receptor blockers were not different. Cardiac rehabilitation was completed in 109 (92%) patients. Underlying conditions were more successfully treated in the intervention group. At 1 year, sinus rhythm was present in 89 (75%) patients in the intervention vs. 79 (63%) in the conventional group (odds ratio 1.765, lower limit of 95% confidence interval 1.021, P  = 0.042). Conclusions RACE 3 confirms that targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent AF. Trial Registration number Clinicaltrials.gov NCT00877643. View large Download slide View large Download slide [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

166. Response to Letter Regarding Article, 'Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation'

Author

Wallentin, Lars, Lopes, Renato D., Hanna, Michael, Thomas, Laine, Hellkamp, Anne, Nepal, Sunil, Hylek, Elaine M., Al-Khatib, Sana M., Alexander, John H., Alings, Marco, Amerena, John, Ansell, Jack, Aylward, Philip, Bartunek, Jozef, Commerford, Patrick, De Caterina, Raffaele, Erol, Cetin, Harjola, Veli-Pekka, Held, Claes, Horowitz, John, Huber, Kurt, Husted, Steen, Keltai, Matyas, Lanas, Fernando, Lisheng, Liu, McMurray, John J. V., Oh, Byung-Hee, Rosenqvist, Marten, Ruzyllo, Witold, Steg, Philippe Gabriel, Vinereanu, Dragos, Xavier, Denis, Granger, Christopher B., Wallentin, Lars, Lopes, Renato D., Hanna, Michael, Thomas, Laine, Hellkamp, Anne, Nepal, Sunil, Hylek, Elaine M., Al-Khatib, Sana M., Alexander, John H., Alings, Marco, Amerena, John, Ansell, Jack, Aylward, Philip, Bartunek, Jozef, Commerford, Patrick, De Caterina, Raffaele, Erol, Cetin, Harjola, Veli-Pekka, Held, Claes, Horowitz, John, Huber, Kurt, Husted, Steen, Keltai, Matyas, Lanas, Fernando, Lisheng, Liu, McMurray, John J. V., Oh, Byung-Hee, Rosenqvist, Marten, Ruzyllo, Witold, Steg, Philippe Gabriel, Vinereanu, Dragos, Xavier, Denis, and Granger, Christopher B.

Published
2014
Full Text
View/download PDF

167. Author reply : To PMID 23625942

Author

Heidbuchel, Hein, Verhamme, Peter, Alings, Marco, Antz, Matthias, Hacke, Werner, Oldgren, Jonas, Sinnaeve, Peter, Camm, A John, Kirchhof, Paulus, Heidbuchel, Hein, Verhamme, Peter, Alings, Marco, Antz, Matthias, Hacke, Werner, Oldgren, Jonas, Sinnaeve, Peter, Camm, A John, and Kirchhof, Paulus

Published
2014
Full Text
View/download PDF

168. E-Health to Manage Distress in Patients With an Implantable Cardioverter-Defibrillator

Author

Habibović, Mirela, primary, Denollet, Johan, additional, Cuijpers, Pim, additional, Spek, Viola R.M., additional, van den Broek, Krista C., additional, Warmerdam, Lisanne, additional, van der Voort, Pepijn H., additional, Herrman, Jean-Paul, additional, Bouwels, Leon, additional, Valk, Suzanne S.D., additional, Alings, Marco, additional, Theuns, Dominic A.M.J., additional, and Pedersen, Susanne S., additional

Published
2014
Full Text
View/download PDF

171. DIFFERENCES BETWEEN HS-TROP T AND NT-PROBNP AS PREDICTORS FOR CARDIOVASCULAR OUTCOMES IN PATIENTS WITH PERMANENT ATRIAL FIBRILLATION: DATA FROM THE RACE II STUDY

Author

Mulder, Bart, primary, van Veldhuisen, Dirk, additional, Crijns, Harry J.G.M., additional, Hillege, Hans L., additional, Tijssen, Jan G., additional, Alings, Marco, additional, van den Berg, Maarten P., additional, Van Gelder, Isabelle, additional, and Rienstra, Michiel, additional

Published
2014
Full Text
View/download PDF

173. Response to Letter Regarding Article, “Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation”

Author

Wallentin, Lars, primary, Lopes, Renato D., additional, Hanna, Michael, additional, Thomas, Laine, additional, Hellkamp, Anne, additional, Nepal, Sunil, additional, Hylek, Elaine M., additional, Al-Khatib, Sana M., additional, Alexander, John H., additional, Alings, Marco, additional, Amerena, John, additional, Ansell, Jack, additional, Aylward, Philip, additional, Bartunek, Jozef, additional, Commerford, Patrick, additional, De Caterina, Raffaele, additional, Erol, Cetin, additional, Harjola, Veli-Pekka, additional, Held, Claes, additional, Horowitz, John, additional, Huber, Kurt, additional, Husted, Steen, additional, Keltai, Matyas, additional, Lanas, Fernando, additional, Lisheng, Liu, additional, McMurray, John J. V., additional, Oh, Byung-Hee, additional, Rosenqvist, Mårten, additional, Ruzyllo, Witold, additional, Steg, Philippe Gabriel, additional, Vinereanu, Dragos, additional, Xavier, Denis, additional, and Granger, Christopher B., additional

Published
2014
Full Text
View/download PDF

174. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation

Author

Wallentin, Lars, Lopes, Renato D, Hanna, Michael, Thomas, Laine, Hellkamp, Anne, Nepal, Sunil, Hylek, Elaine M, Al-Khatib, Sana M, Alexander, John H, Alings, Marco, Amerena, John, Ansell, Jack, Aylward, Philip, Bartunek, Jozef, Commerford, Patrick, De Caterina, Raffaele, Erol, Cetin, Harjola, Veli-Pekka, Held, Claes, Horowitz, John D, Huber, Kurt, Husted, Steen, Keltai, Matyas, Lanas, Fernando, Lisheng, Liu, McMurray, John J V, Oh, Byung-Hee, Rosenqvist, Mårten, Ruzyllo, Witold, Steg, Philippe Gabriel, Vinereanu, Dragos, Xavier, Denis, Granger, Christopher B, Wallentin, Lars, Lopes, Renato D, Hanna, Michael, Thomas, Laine, Hellkamp, Anne, Nepal, Sunil, Hylek, Elaine M, Al-Khatib, Sana M, Alexander, John H, Alings, Marco, Amerena, John, Ansell, Jack, Aylward, Philip, Bartunek, Jozef, Commerford, Patrick, De Caterina, Raffaele, Erol, Cetin, Harjola, Veli-Pekka, Held, Claes, Horowitz, John D, Huber, Kurt, Husted, Steen, Keltai, Matyas, Lanas, Fernando, Lisheng, Liu, McMurray, John J V, Oh, Byung-Hee, Rosenqvist, Mårten, Ruzyllo, Witold, Steg, Philippe Gabriel, Vinereanu, Dragos, Xavier, Denis, and Granger, Christopher B

Abstract

Background In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR). Methods and Results The trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 months. For each patient, a center average TTR was estimated with the use of a linear mixed model on the basis of the real TTRs in its warfarin-treated patients, with a fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient characteristics as well. Median center average TTR was 66% (interquartile limits, 61% and 71%). Rates of stroke or systemic embolism, major bleeding, and mortality were consistently lower with apixaban than with warfarin across center average TTR and individual TTR quartiles. In the lowest and highest center average TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI], 0.53–1.00) and 0.88 (95% CI, 0.57–1.35) (Pinteraction=0.078), for mortality were 0.91 (95% CI, 0.74–1.13) and 0.91 (95% CI, 0.71–1.16) (Pinteraction=0.34), and for major bleeding were 0.50 (95% CI, 0.36–0.70) and 0.75 (95% CI, 0.58–0.97) (Pinteraction=0.095), respectively. Similar results were seen for quartiles of individual TTR. Conclusions The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.

Published
2013
Full Text
View/download PDF

175. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Author

Connolly, Stuart J., Wallentin, Lars, Ezekowitz, Michael D., Eikelboom, John, Oldgren, Jonas, Reilly, Paul A., Brueckmann, Martina, Pogue, Janice, Alings, Marco, Amerena, John V., Avezum, Alvaro, Baumgartner, Iris, Budaj, Andrzej J., Chen, Jyh-Hong, Dans, Antonio L., Darius, Harald, Di Pasquale, Giuseppe, Ferreira, Jorge, Flaker, Greg C., Flather, Marcus D., Franzosi, Maria Grazia, Golitsyn, Sergey P., Halon, David A., Heidbuchel, Hein, Hohnloser, Stefan H., Huber, Kurt, Jansky, Petr, Kamensky, Gabriel, Keltai, Matyas, Kim, Sung Soon, Lau, Chu-Pak, Le Heuzey, Jean-Yves, Lewis, Basil S., Liu, Lisheng, Nanas, John, Omar, Razali, Pais, Prem, Pedersen, Knud E., Piegas, Leopoldo S., Raev, Dimitar, Smith, Pal J., Talajic, Mario, Tan, Ru San, Tanomsup, Supachai, Toivonen, Lauri, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Wang, Susan Q., Duffy, Christine O., Themeles, Ellison, Yusuf, Salim, Connolly, Stuart J., Wallentin, Lars, Ezekowitz, Michael D., Eikelboom, John, Oldgren, Jonas, Reilly, Paul A., Brueckmann, Martina, Pogue, Janice, Alings, Marco, Amerena, John V., Avezum, Alvaro, Baumgartner, Iris, Budaj, Andrzej J., Chen, Jyh-Hong, Dans, Antonio L., Darius, Harald, Di Pasquale, Giuseppe, Ferreira, Jorge, Flaker, Greg C., Flather, Marcus D., Franzosi, Maria Grazia, Golitsyn, Sergey P., Halon, David A., Heidbuchel, Hein, Hohnloser, Stefan H., Huber, Kurt, Jansky, Petr, Kamensky, Gabriel, Keltai, Matyas, Kim, Sung Soon, Lau, Chu-Pak, Le Heuzey, Jean-Yves, Lewis, Basil S., Liu, Lisheng, Nanas, John, Omar, Razali, Pais, Prem, Pedersen, Knud E., Piegas, Leopoldo S., Raev, Dimitar, Smith, Pal J., Talajic, Mario, Tan, Ru San, Tanomsup, Supachai, Toivonen, Lauri, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Wang, Susan Q., Duffy, Christine O., Themeles, Ellison, and Yusuf, Salim

Abstract

Background During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses. Methods and Results Patients randomly assigned to dabigatran in RE-LY were eligible for the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial if they had not permanently discontinued study medication at the time of their final RE-LY study visit. Enrolled patients continued to receive the double-blind dabigatran dose received in RE-LY, for up to 28 months of follow up after RE-LY (median follow-up, 2.3 years). There were 5851 patients enrolled, representing 48% of patients originally randomly assigned to receive dabigatran in RE-LY and 86% of RELY-ABLE-eligible patients. Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 150 and 110 mg twice daily, respectively (hazard ratio, 0.91; 95% confidence interval, 0.69-1.20). Rates of major hemorrhage were 3.74% and 2.99%/y on dabigatran 150 and 110 mg (hazard ratio, 1.26; 95% confidence interval, 1.04-1.53). Rates of death were 3.02% and 3.10%/y (hazard ratio, 0.97; 95% confidence interval, 0.80-1.19). Rates of hemorrhagic stroke were 0.13% and 0.14%/y. Conclusions During 2.3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death., Clinical Trial Registration URL: Unique identifier: NCT00808067.

Published
2013
Full Text
View/download PDF

176. Reply to Letters Regarding Article : 'Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial'

Author

Eikelboom, John W., Connolly, Stuart J., Healey, Jeff S., Yang, Sean, Yusuf, Salim, Wallentin, Lars, Oldgren, Jonas, Ezekowitz, Mike, Alings, Marco, Kaatz, Scott, Hohnloser, Stefan H., Diener, Hans-Christoph, Franzosi, Maria Grazia, Huber, Kurt, Reilly, Paul, Varrone, Jeanne, Eikelboom, John W., Connolly, Stuart J., Healey, Jeff S., Yang, Sean, Yusuf, Salim, Wallentin, Lars, Oldgren, Jonas, Ezekowitz, Mike, Alings, Marco, Kaatz, Scott, Hohnloser, Stefan H., Diener, Hans-Christoph, Franzosi, Maria Grazia, Huber, Kurt, Reilly, Paul, and Varrone, Jeanne

Published
2012
Full Text
View/download PDF

177. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of the ARISTOTLE trial

Author

Easton, J. Donald, Lopes, Renato D., Bahit, M. Cecilia, Wojdyla, Daniel M., Granger, Christopher B., Wallentin, Lars, Alings, Marco, Goto, Shinya, Lewis, Basil S., Rosenqvist, Marten, Hanna, Michael, Mohan, Puneet, Alexander, John H., Diener, Hans-Christoph, Easton, J. Donald, Lopes, Renato D., Bahit, M. Cecilia, Wojdyla, Daniel M., Granger, Christopher B., Wallentin, Lars, Alings, Marco, Goto, Shinya, Lewis, Basil S., Rosenqvist, Marten, Hanna, Michael, Mohan, Puneet, Alexander, John H., and Diener, Hans-Christoph

Abstract

Background In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA. Methods Between Dec 19,2006, and April 2,2010, patients were enrolled in the ARISTOTLE trial at 1034 clinical sites in 39 countries. 18 201 patients with AF or atrial flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target international normalised ratio 2.0-3.0). The median duration of follow-up was 1.8 years (IQR 1.4-2.3). The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat. The primary safety outcome was major bleeding in the on-treatment population. All participants, investigators, and sponsors were masked to treatment assignments. In this subgroup analysis, we estimated event rates and used Cox models to compare outcomes in patients with and without previous stroke or TIA. The ARISTOTLE trial is registered with ClinicalTrials.gov, number NTC00412984. Findings Of the trial population, 3436 (19%) had a previous stroke or TIA. In the subgroup of patients with previous stroke or TIA, the rate of stroke or systemic embolism was 2.46 per 100 patient-years of follow-up in the apixaban group and 3.24 in the warfarin group (hazard ratio [HR] 0.76, 95% CI 0.56 to 1.03); in the subgroup of patients without previous stroke or TLA, the rate of stroke or systemic embolism was 1.01 per 100 patient-years of follow-up with apixaban and 1.23 with warfarin (HR 0.82, 95% CI 0.65 to 1.03; p for interaction=0.71). The absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0.77 per 100 patient-years of follow-up (95% CI -0.08 to 1.63) in patients

Published
2012
Full Text
View/download PDF

178. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

Author

UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, UCL - (MGD) Service de cardiologie, Easton, J Donald, Lopes, Renato D, Bahit, M Cecilia, Wojdyla, Daniel M, Granger, Christopher B, Wallentin, Lars, Alings, Marco, Goto, Shinya, ARISTOTLE Committees and Investigators, Lewis, Basil S, Rosenqvist, Mårten, Deceuninck, Olivier, Hanna, Michael, Mohan, Puneet, Alexander, John H, Diener, Hans-Christoph, Peeters, André, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, UCL - (MGD) Service de cardiologie, Easton, J Donald, Lopes, Renato D, Bahit, M Cecilia, Wojdyla, Daniel M, Granger, Christopher B, Wallentin, Lars, Alings, Marco, Goto, Shinya, ARISTOTLE Committees and Investigators, Lewis, Basil S, Rosenqvist, Mårten, Deceuninck, Olivier, Hanna, Michael, Mohan, Puneet, Alexander, John H, Diener, Hans-Christoph, and Peeters, André

Abstract

BACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA. METHODS: Between Dec 19, 2006, and April 2, 2010, patients were enrolled in the ARISTOTLE trial at 1034 clinical sites in 39 countries. 18,201 patients with AF or atrial flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target international normalised ratio 2·0-3·0). The median duration of follow-up was 1·8 years (IQR 1·4-2·3). The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat. The primary safety outcome was major bleeding in the on-treatment population. All participants, investigators, and sponsors were masked to treatment assignments. In this subgroup analysis, we estimated event rates and used Cox models to compare outcomes in patients with and without previous stroke or TIA. The ARISTOTLE trial is registered with ClinicalTrials.gov, number NTC00412984. FINDINGS: Of the trial population, 3436 (19%) had a previous stroke or TIA. In the subgroup of patients with previous stroke or TIA, the rate of stroke or systemic embolism was 2·46 per 100 patient-years of follow-up in the apixaban group and 3·24 in the warfarin group (hazard ratio [HR] 0·76, 95% CI 0·56 to 1·03); in the subgroup of patients without previous stroke or TIA, the rate of stroke or systemic embolism was 1·01 per 100 patient-years of follow-up with apixaban and 1·23 with warfarin (HR 0·82, 95% CI 0·65 to 1·03; p for interaction=0·71). The absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0·77 per 100 patient-years of follow-up (95% CI -0·08 to 1·63) in pati

Published
2012

179. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack:a subgroup analysis of the ARISTOTLE trial

Author

Easton, J Donald, Lopes, Renato D, Bahit, M Cecilia, Wojdyla, Daniel M, Granger, Christopher B, Wallentin, Lars, Alings, Marco, Goto, Shinya, Lewis, Basil S, Rosenqvist, Mårten, Hanna, Michael, Mohan, Puneet, Alexander, John H, Diener, Hans-Christoph, Torp-Pedersen, Christian Tobias, Easton, J Donald, Lopes, Renato D, Bahit, M Cecilia, Wojdyla, Daniel M, Granger, Christopher B, Wallentin, Lars, Alings, Marco, Goto, Shinya, Lewis, Basil S, Rosenqvist, Mårten, Hanna, Michael, Mohan, Puneet, Alexander, John H, Diener, Hans-Christoph, and Torp-Pedersen, Christian Tobias

Abstract

In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.

Published
2012

180. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Author

Eikelboom, John W., Wallentin, Lars, Connolly, Stuart J., Ezekowitz, Mike, Healey, Jeff S., Oldgren, Jonas, Yang, Sean, Alings, Marco, Kaatz, Scott, Hohnloser, Stefan H., Diener, Hans-Christoph, Franzosi, Maria Grazia, Huber, Kurt, Reilly, Paul, Varrone, Jeanne, Yusuf, Salim, Eikelboom, John W., Wallentin, Lars, Connolly, Stuart J., Ezekowitz, Mike, Healey, Jeff S., Oldgren, Jonas, Yang, Sean, Alings, Marco, Kaatz, Scott, Hohnloser, Stefan H., Diener, Hans-Christoph, Franzosi, Maria Grazia, Huber, Kurt, Reilly, Paul, Varrone, Jeanne, and Yusuf, Salim

Abstract

Background-Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and Results-The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged = 75 years (4.43% versus 4.37%; P=0.89; P for interaction = 75 years (5.10% versus 4.37%; P=0.07; P for interaction = 75 years, intracranial bleeding risk is lower but extracranial bleeding risk is similar or higher with both doses of dabigatran compared with warfarin.

Published
2011
Full Text
View/download PDF

181. Dronedarone in High-Risk Permanent Atrial Fibrillation

Author

Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Alvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Alvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, and Hohnloser, Stefan H

Abstract

Background Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular anti-arrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. Methods We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Results After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Conclusions Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients.

Published
2011
Full Text
View/download PDF

182. Dronedarone in high-risk permanent atrial fibrillation.

Author

UCL - (MGD) Service de cardiologie, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, PALLAS Investigators, Deceuninck, Olivier, UCL - (MGD) Service de cardiologie, Connolly, Stuart J, Camm, A John, Halperin, Jonathan L, Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B, Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S, Merino, Jose L, Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S, Sim, Kui-Hian, Stiles, Martin K, Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H, PALLAS Investigators, and Deceuninck, Olivier

Abstract

Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).

Published
2011

183. Large-scale gene-centric analysis identifies novel variants for coronary artery disease

Author

Butterworth, Adam S., Braund, Peter S., Farrall, Martin, Hardwick, Robert J., Saleheen, Danish, Peden, John F., Soranzo, Nicole, Chambers, John C., Sivapalaratnam, Suthesh, Kleber, Marcus E., Keating, Brendan, Qasim, Atif, Klopp, Norman, Erdmann, Jeanette, Assimes, Themistocles L., Ball, Stephen G., Balmforth, Anthony J., Barnes, Timothy A., Basart, Hanneke, Baumert, Jens, Bezzina, Connie R., Boerwinkle, Eric, Boehm, Bernhard O., Brocheton, Jessy, Bugert, Peter, Cambien, Francois, Clarke, Robert, Codd, Veryan, Collins, Rory, Couper, David, Adrienne Cupples, L., de Jong, Jonas S., Diemert, Patrick, Ejebe, Kenechi, Elbers, Clara C., Elliott, Paul, Fornage, Myriam, Franzosi, Maria Grazia, Frossard, Philippe, Garner, Stephen, Goel, Anuj, Goodall, Alison H., Hengstenberg, Christian, Hunt, Sarah E., Bruinsma, Nienke, Alings, Marco, Shah, S., Dehghan, Abbas, Hofman, Albert, Uitterlinden, Andre G., Butterworth, Adam S., Braund, Peter S., Farrall, Martin, Hardwick, Robert J., Saleheen, Danish, Peden, John F., Soranzo, Nicole, Chambers, John C., Sivapalaratnam, Suthesh, Kleber, Marcus E., Keating, Brendan, Qasim, Atif, Klopp, Norman, Erdmann, Jeanette, Assimes, Themistocles L., Ball, Stephen G., Balmforth, Anthony J., Barnes, Timothy A., Basart, Hanneke, Baumert, Jens, Bezzina, Connie R., Boerwinkle, Eric, Boehm, Bernhard O., Brocheton, Jessy, Bugert, Peter, Cambien, Francois, Clarke, Robert, Codd, Veryan, Collins, Rory, Couper, David, Adrienne Cupples, L., de Jong, Jonas S., Diemert, Patrick, Ejebe, Kenechi, Elbers, Clara C., Elliott, Paul, Fornage, Myriam, Franzosi, Maria Grazia, Frossard, Philippe, Garner, Stephen, Goel, Anuj, Goodall, Alison H., Hengstenberg, Christian, Hunt, Sarah E., Bruinsma, Nienke, Alings, Marco, Shah, S., Dehghan, Abbas, Hofman, Albert, and Uitterlinden, Andre G.

Abstract

Coronary artery disease (CAD) has a significant genetic contribution that is incompletely characterized. To complement genome-wide association (GWA) studies, we conducted a large and systematic candidate gene study of CAD susceptibility, including analysis of many uncommon and functional variants. We examined 49,094 genetic variants in ~2,100 genes of cardiovascular relevance, using a customised gene array in 15,596 CAD cases and 34,992 controls (11,202 cases and 30,733 controls of European descent; 4,394 cases and 4,259 controls of South Asian origin). We attempted to replicate putative novel associations in an additional 17,121 CAD cases and 40,473 controls. Potential mechanisms through which the novel variants could affect CAD risk were explored through association tests with vascular risk factors and gene expression. We confirmed associations of several previously known CAD susceptibility loci (eg, 9p21.3:p<10-33; LPA:p<10-19; 1p13.3:p<10-17) as well as three recently discovered loci (COL4A1/COL4A2, ZC3HC1, CYP17A1:p<5×10-7). However, we found essentially null results for most previously suggested CAD candidate genes. In our replication study of 24 promising common variants, we identified novel associations of variants in or near LIPA, IL5, TRIB1, and ABCG5/ABCG8, with per-allele odds ratios for CAD risk with each of the novel variants ranging from 1.06-1.09. Associations with variants at LIPA, TRIB1, and ABCG5/ABCG8 were supported by gene expression data or effects on lipid levels. Apart from the previously reported variants in LPA, none of the other ~4,500 low frequency and functional variants showed a strong effect. Associations in South Asians did not differ appreciably from those in Europeans, except for 9p21.3 (per-allele odds ratio: 1.14 versus 1.27 respectively; P for heterogeneity = 0.003). This large-scale gene-centric analysis has identified several novel genes for CAD that relate to diverse b

Published
2011

185. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Author

Connolly, Stuart J., primary, Wallentin, Lars, additional, Ezekowitz, Michael D., additional, Eikelboom, John, additional, Oldgren, Jonas, additional, Reilly, Paul A., additional, Brueckmann, Martina, additional, Pogue, Janice, additional, Alings, Marco, additional, Amerena, John V., additional, Avezum, Alvaro, additional, Baumgartner, Iris, additional, Budaj, Andrzej J., additional, Chen, Jyh-Hong, additional, Dans, Antonio L., additional, Darius, Harald, additional, Di Pasquale, Giuseppe, additional, Ferreira, Jorge, additional, Flaker, Greg C., additional, Flather, Marcus D., additional, Franzosi, Maria Grazia, additional, Golitsyn, Sergey P., additional, Halon, David A., additional, Heidbuchel, Hein, additional, Hohnloser, Stefan H., additional, Huber, Kurt, additional, Jansky, Petr, additional, Kamensky, Gabriel, additional, Keltai, Matyas, additional, Kim, Sung Soon, additional, Lau, Chu-Pak, additional, Le Heuzey, Jean-Yves, additional, Lewis, Basil S., additional, Liu, Lisheng, additional, Nanas, John, additional, Omar, Razali, additional, Pais, Prem, additional, Pedersen, Knud E., additional, Piegas, Leopoldo S., additional, Raev, Dimitar, additional, Smith, Pal J., additional, Talajic, Mario, additional, Tan, Ru San, additional, Tanomsup, Supachai, additional, Toivonen, Lauri, additional, Vinereanu, Dragos, additional, Xavier, Denis, additional, Zhu, Jun, additional, Wang, Susan Q., additional, Duffy, Christine O., additional, Themeles, Ellison, additional, and Yusuf, Salim, additional

Published
2013
Full Text
View/download PDF

186. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation

Author

Wallentin, Lars, primary, Lopes, Renato D., additional, Hanna, Michael, additional, Thomas, Laine, additional, Hellkamp, Anne, additional, Nepal, Sunil, additional, Hylek, Elaine M., additional, Al-Khatib, Sana M., additional, Alexander, John H., additional, Alings, Marco, additional, Amerena, John, additional, Ansell, Jack, additional, Aylward, Philip, additional, Bartunek, Jozef, additional, Commerford, Patrick, additional, De Caterina, Raffaele, additional, Erol, Cetin, additional, Harjola, Veli-Pekka, additional, Held, Claes, additional, Horowitz, John D., additional, Huber, Kurt, additional, Husted, Steen, additional, Keltai, Matyas, additional, Lanas, Fernando, additional, Lisheng, Liu, additional, McMurray, John J.V., additional, Oh, Byung-Hee, additional, Rosenqvist, Mårten, additional, Ruzyllo, Witold, additional, Steg, Philippe Gabriel, additional, Vinereanu, Dragos, additional, Xavier, Denis, additional, and Granger, Christopher B., additional

Published
2013
Full Text
View/download PDF

187. Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT)

Author

Connolly, Stuart J., primary, Philippon, Francois, additional, Longtin, Yves, additional, Casanova, Amparo, additional, Birnie, David H., additional, Exner, Derek V., additional, Dorian, Paul, additional, Prakash, Ratika, additional, Alings, Marco, additional, and Krahn, Andrew D., additional

Published
2013
Full Text
View/download PDF

192. Abstract 18466: Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial

Author

Westenbrink, B. Daan, primary, Alings, Marco, additional, Connolly, Stuart, additional, Eikelboom, John, additional, Ezekowitz, Michael D, additional, Oldgren, Jonas, additional, Yang, Sean, additional, Pogue, Janice, additional, Yusuf, Salim, additional, Wallentin, Lars, additional, and van Gilst, Wiek H, additional

Published
2012
Full Text
View/download PDF

194. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Author

Easton, J Donald, primary, Lopes, Renato D, additional, Bahit, M Cecilia, additional, Wojdyla, Daniel M, additional, Granger, Christopher B, additional, Wallentin, Lars, additional, Alings, Marco, additional, Goto, Shinya, additional, Lewis, Basil S, additional, Rosenqvist, Mårten, additional, Hanna, Michael, additional, Mohan, Puneet, additional, Alexander, John H, additional, and Diener, Hans-Christoph, additional

Published
2012
Full Text
View/download PDF

195. EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN

Author

Alexander, John H., primary, Lopes, Renato, additional, McMurray, John, additional, Atar, Dan, additional, Wojdyla, Daniel, additional, Aylward, Philip, additional, Husted, Steen, additional, Alings, Marco, additional, Huber, Kurt, additional, Hanna, Michael, additional, Pais, Prem, additional, Lewis, Basil, additional, Goto, Shinya, additional, Pouleur, Hubert, additional, Steg, Philippe, additional, Verheugt, Freek, additional, Granger, Christopher, additional, and Wallentin, Lars, additional

Published
2012
Full Text
View/download PDF

196. Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”

Author

Eikelboom, John W., primary, Connolly, Stuart J., additional, Healey, Jeff S., additional, Yang, Sean, additional, Yusuf, Salim, additional, Wallentin, Lars, additional, Oldgren, Jonas, additional, Ezekowitz, Mike, additional, Alings, Marco, additional, Kaatz, Scott, additional, Hohnloser, Stefan H., additional, Diener, Hans-Christoph, additional, Franzosi, Maria Grazia, additional, Huber, Kurt, additional, Reilly, Paul, additional, and Varrone, Jeanne, additional

Published
2012
Full Text
View/download PDF

197. Subclinical Atrial Fibrillation in Older Patients

Author

Healey, Jeff S., Alings, Marco, Ha, Andrew, Leong-Sit, Peter, Birnie, David H., de Graaf, Jacob J., Freericks, Michel, Verma, Atul, Wang, Jia, Leong, Darryl, Dokainish, Hisham, Philippon, Francois, Barake, Walid, McIntyre, William F., Simek, Kim, Hill, Michael D., Mehta, Shamir R., Carlson, Mark, Smeele, Frank, Pandey, A. Shekhar, and Connolly, Stuart J.

Abstract

Supplemental Digital Content is available in the text.

Published
2017
Full Text
View/download PDF

198. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies(COMPASS) Trial

Author

Bosch, Jackie, Eikelboom, John W., Connolly, Stuart J., Bruns, Nancy Cook, Lanius, Vivian, Yuan, Fei, Misselwitz, Frank, Chen, Edmond, Diaz, Rafael, Alings, Marco, Lonn, Eva M., Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S., Bhatt, Deepak L., Branch, Kelley R.H., Probstfield, Jeffrey L., Liang, Yan, Liu, Lisheng, Zhu, Jun, Maggioni, Aldo P., Lopez-Jaramillo, Patricio, O'Donnell, Martin, Fox, Keith A.A., Kakkar, Ajay, Parkhomenko, Alexander N., Ertl, Georg, Störk, Stefan, Keltai, Katalin, Keltai, Matyas, Ryden, Lars, Dagenais, Gilles R., Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomasz J., Verhamme, Peter B., Vinereanu, Dragos, Kim, Jae-Hyung, Ha, Jong-Won, Tonkin, Andrew M., Varigos, John D., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Steg, Philippe Gabriel, Aboyans, Victor, Metsarinne, Kaj P., Anand, Sonia S., Hart, Robert G., Lamy, Andre, Moayyedi, Paul, Leong, Darryl P., Sharma, Mukul, and Yusuf, Salim

Abstract

Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results